ATS-9R: Targeted Non-Viral Gene Delivery to White Adipose Tissue

Executive Summary: ATS-9R (Adipocyte-targeting sequence-9-arginine, SKU: C8721) is a fusion oligopeptide designed for non-viral, targeted gene delivery to white adipose tissue via prohibitin-mediated endocytosis (Won et al., 2014). It selectively binds mature adipocytes and adipose tissue macrophages, facilitating efficient nucleic acid condensation and intracellular release. ATS-9R/shRNA complexes achieve 30–70% mRNA knockdown of target genes with minimal cytotoxicity and off-target distribution (APExBIO). Nanoparticles formed are 150–354 nm in size, with a zeta potential of 7–20 mV, and are cleared via the liver within 24 hours. This system enables advanced research in obesity, insulin resistance, and gestational diabetes models (CRISPR-CASY).

Biological Rationale

White adipose tissue (WAT) is the primary site of long-term energy storage and a major source of pro-inflammatory cytokines in obesity (Won et al., 2014). Traditional anti-obesity drugs targeting the central nervous or gastrointestinal systems often show limited efficacy and significant adverse effects due to off-target activity (Fig. 1A). Targeting adipocytes directly enables localized intervention in metabolic pathways critical for lipid storage, inflammation, and insulin sensitivity. Prohibitin, a conserved protein, is highly expressed on mature adipocyte surfaces and adipose vasculature, making it an ideal molecular target for selective delivery (Won et al., 2014). By delivering nucleic acids directly to adipocytes, ATS-9R enables gene-specific modulation with minimal systemic exposure.

Mechanism of Action of ATS-9R (Adipocyte-targeting sequence-9-arginine)

ATS-9R is a synthetic oligopeptide with the sequence Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Cys (APExBIO). The N-terminal CKGGRAKDC motif binds specifically to prohibitin on mature adipocytes and adipose tissue macrophages (Won et al., 2014). Upon binding, the peptide triggers prohibitin-mediated endocytosis, internalizing the peptide-nucleic acid complex. The C-terminal nona-arginine (9R) stretch condenses nucleic acids (shRNA, sgRNA/Cas9, etc.), improving cellular uptake and endosomal escape. Intracellular release of nucleic acids achieves sequence-specific gene silencing (CRISPR-CASY, 2023). This targeted approach distinguishes ATS-9R from non-specific polycationic carriers, reducing off-target delivery and systemic toxicity.

Evidence & Benchmarks

• ATS-9R/shFABP4 complexes induce >20% body weight reduction in obese mice after 5 weeks of treatment (Won et al., 2014).
• Gene silencing efficiency of 30–70% mRNA knockdown for target genes (e.g., Fabp4, TACE, CCL2, FAM83A) after four intraperitoneal injections at 0.35–0.7 mg/kg nucleic acid in mice (APExBIO).
• Nanoparticle complexes formed at 3:1 or 6:1 peptide:nucleic acid weight ratio, with mean diameter 150–354 nm and zeta potential 7–20 mV; stability confirmed via agarose gel retardation assays (Won et al., 2014).
• Low cytotoxicity demonstrated by cell viability >80% in 3T3-L1 and primary adipocyte cultures at 10–25 μg/ml peptide and 5 μM–2 μg nucleic acid concentrations (CRISPR-CASY).
• In vivo, complexes preferentially accumulate in visceral (epiWAT) and subcutaneous (subWAT) adipose tissue, with minimal hepatic or renal side effects (Won et al., 2014).
• Liver acts as clearance organ; ATS-9R complexes cleared within 12–24 hours post-injection in mice (APExBIO).

This article extends the discussion in ATS-9R: Non-Viral Gene Delivery to White Adipose Tissue by providing updated quantitative benchmarks, mechanistic clarifications, and highlighting the product’s translational workflow integration. For a broader mechanistic review, see Redefining Targeted Gene Delivery: Mechanistic Insights and Translational Strategies, which discusses emerging applications and experimental design strategies for ATS-9R in metabolic disease models.

Applications, Limits & Misconceptions

ATS-9R is validated for targeted delivery of shRNA, sgRNA/Cas9, and other nucleic acids to mature adipocytes and adipose tissue macrophages. Key applications include:

• Obesity-associated inflammation research via silencing of CCL2, TACE, and other pro-inflammatory genes (Won et al., 2014).
• Amelioration of insulin resistance and metabolic syndrome by modulating adipokine expression (CRISPR-CASY).
• Gestational diabetes mellitus (GDM) and obesity-induced type 2 diabetes research (APExBIO).
• Reduction of fat accumulation by targeting lipid chaperones such as Fabp4 (Won et al., 2014).

Notably, ATS-9R complexes show minimal cytotoxicity and do not trigger significant hepatic or renal toxicity at validated doses (cell viability >80%; normal liver/kidney histology) (Won et al., 2014).

Common Pitfalls or Misconceptions

• Not suitable for brown adipose tissue targeting: ATS-9R binds prohibitin, which is specifically upregulated in mature white adipocytes, not brown adipocytes (Won et al., 2014).
• Ineffective for non-adipocyte cell types: The peptide’s specificity is limited to cells expressing surface prohibitin at high levels.
• Not compatible with viral vector delivery systems: ATS-9R is designed for non-viral nucleic acid complexation.
• Loss of targeting efficiency if stored improperly: Elevated temperatures or repeated freeze-thaw cycles degrade the peptide; store at -20°C and prepare fresh (APExBIO).
• Not a direct therapeutic: ATS-9R is a research reagent and should not be interpreted as a clinical drug product.

Workflow Integration & Parameters

To maximize efficacy, nucleic acid/ATS-9R complexes should be prepared at a 3:1 or 6:1 (w/w) ratio in serum-free buffer. Confirm condensation via agarose gel retardation. The resulting nanoparticles (150–354 nm, zeta potential 7–20 mV) are suitable for in vitro or in vivo use. Typical in vitro concentrations are 10–25 μg/ml peptide with 5 μM–2 μg of nucleic acid in serum-free medium, incubated for 4–6 hours before media replacement. For animal studies, administer 0.2–0.35 mg/kg peptide and 0.35–0.7 mg/kg nucleic acid via intraperitoneal injection twice weekly or as four consecutive doses. Monitor knockdown efficiency by qPCR after 48–96 hours. Store peptide stock in DMSO at -20°C and avoid freeze-thaw cycles (APExBIO).

Conclusion & Outlook

ATS-9R provides a rigorously validated, non-viral gene delivery approach for targeted nucleic acid delivery to white adipose tissue in preclinical research. Its prohibitin-mediated uptake, high nucleic acid condensation, and low toxicity profile make it a leading tool for metabolic disease modeling and gene-function studies. For expanded guidance on troubleshooting and advanced applications, see ATS-9R: Targeted Gene Silencing in Adipocytes for Metabolic Disease Models, which details optimized workflows and experimental considerations beyond the present summary. For product sourcing and additional technical documentation, consult the APExBIO ATS-9R (C8721) product page.